![](/imager/uploads/logos/58681/Avicenna_logo_black_117378e58441a39758ec294c229f7090.webp)
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery
In Newfoundland and Labrador, the founder effect means there’s less genetic variability, making it easier to use population multi-omics to find true signals of disease — gene variants with low frequency but high impact. Sequence Bio works with leading pharma and biotech companies to discover better drug targets, build custom cohorts of volunteers for clinical trials, and shorten R&D timelines.
Using AI to speed through the last mile of drug discovery
Finding precisely tuned viral vectors for gene therapy in CNS disorders
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing